What is the recommended curative treatment for stage I non‑small cell lung cancer?

Stage I Non-Small Cell Lung Cancer: Curative Treatment

For medically fit patients with stage I NSCLC, surgical resection with curative intent is the recommended primary treatment, with minimally invasive surgery preferred over thoracotomy. 1

Primary Treatment Algorithm

For Surgical Candidates (Average or Low Operative Risk)

Surgical resection remains the gold standard for stage I NSCLC in patients who can tolerate the operation 2, 1. The approach should be:

• Minimally invasive surgery (VATS) is preferred over open thoracotomy - Recent meta-analysis demonstrates an association between minimally invasive surgery and better overall survival outcomes 1

Extent of Resection Based on Tumor Characteristics

The surgical approach depends on tumor size and location:

For peripheral tumors ≤ 2 cm with ground-glass/lepidic component:

• Lobectomy, segmentectomy, or wedge resection are equivalent alternatives 1
• Sublobar resection requires margins > 2 cm or margin/tumor ratio > 1 1

For other stage I tumors:

• Lobectomy with systematic mediastinal and hilar lymph node sampling or dissection is standard 1
• Recent evidence shows equivalent overall survival for peripheral ≤ 2 cm NSCLC treated with sublobar resection compared to lobectomy 1

Critical technical requirement: Systematic intraoperative mediastinal and hilar lymph node sampling or dissection must be performed during all operations for stage I NSCLC to ensure accurate staging and guide adjuvant therapy decisions 1

For Non-Surgical Candidates

Stereotactic body radiotherapy (SBRT/SABR) is the preferred approach for patients with stage I NSCLC who are not appropriate candidates for surgical resection 1, 3

Alternative options in select patients:

• Image-guided thermal ablation (IGTA) for patients ineligible for both surgery and SABR 3

Adjuvant Therapy Considerations

For Resected Stage IB (≥ 3 cm) with EGFR Mutations:

• Adjuvant targeted therapy improves overall survival 1

Emerging Paradigm Shift:

The treatment landscape is evolving with immune checkpoint inhibitors and targeted therapies, historically used in advanced disease, now being investigated for resectable early-stage NSCLC 2. This represents a paradigm shift from the modest benefits previously seen with platinum-based chemotherapy alone.

Key Clinical Pitfalls to Avoid

1. Inadequate lymph node assessment: Failure to perform systematic lymph node sampling/dissection compromises staging accuracy and may lead to undertreatment

2. Inappropriate use of sublobar resection: Only use for peripheral tumors ≤ 2 cm; ensure adequate margins (> 2 cm or ratio > 1) 1

3. Missing molecular testing: For tumors ≥ 3 cm (stage IB), EGFR mutation testing is essential to identify candidates for adjuvant targeted therapy 1

4. Defaulting to thoracotomy: Minimally invasive approaches should be the default when technically feasible, given survival advantages 1

Multi-Disciplinary Decision-Making

For high-risk surgical patients, a multi-disciplinary review is essential to weigh:

• Patient functional status and comorbidities
• Tumor characteristics (size, location, histology)
• Patient preferences and quality of life considerations
• Availability of SABR if surgery is declined or contraindicated 3

If possible, obtaining a tissue biopsy is very important prior to non-surgical treatment to confirm diagnosis and enable molecular profiling 3.